Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1711)
  2. Journal Article (1446)
  3. Review (84)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (11)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3406)
  2. Solid Tumor Oncology Division (3406)
  3. GSK Faculty (1075)
  4. Department of Pathology and Laboratory Medicine (821)
  5. Hematology-Oncology Fellows (715)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (664)

More Groups

People
  1. Mark Kris (873)
  2. Alexander Drilon (639)
  3. Gregory Riely (606)
  4. Charles Rudin (497)
  5. Marc Ladanyi (419)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (126)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (704)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (159)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (90)

More Publications

Publishers
  1. American Society of Clinical Oncology (783)
  2. Elsevier Inc. (741)
  3. American Association for Cancer Research (387)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (80)

More Publishers

Results (3406)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment sequencing in the VISION study of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
    Meeting Abstract

    Griesingerl, F.; Garassino, M.; Felip, E.; Sakai, H.; Le, X.; Veillon, R.; Smit, E.; Raskin, J.; Thomas, M.; Ahn, M. J.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC
    Meeting Abstract

    Nishio, M.; Negrao, M. V.; Arbour, K. C.; Burns, T. F.; Cappuzzo, F.; Dingemans, A. M. C.; Girard, N.; Gronberg, B. H.; Hochmair, M.; Leal, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and clinicogenomic biomarkers of response to dual versus single agent checkpoint inhibitor therapy in untreated metastatic non-small cell lung cancer
    Meeting Abstract

    Boiarsky, D.; Hong, L.; Ricciuti, B.; Cooper, A. J.; Saad, M. B.; Elkrief, A.; Di Federico, A.; Aminu, M.; Rinsurongkawong, W.; Lewis, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
    Meeting Abstract

    Garassino, M. C.; Wakelee, H. A.; Spicer, J.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; Chen, K. N.; Dooms, C. A.; Majem, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC)
    Meeting Abstract

    Cabanillas, M. E.; Lin, J. J.; Brose, M. S.; McDermott, R. S.; Almubarak, M.; Bauman, J. R.; Casanova, M.; Kummar, S.; Lee, S. H.; Leyvraz, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK plus non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Jayakrishnan, R.; Nassar, A.; Shepherd, F. A.; Lin, J. J.; Lin, S. H.; Shakya, P.; Dilling, T. J.; Bar, J.; Grohe, C.; Gupta, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies
    Meeting Abstract

    Drilon, A. E.; Dziadziuszko, R.; Camidge, D. R.; Lin, J. J.; Besse, B.; Kim, S. W.; Lee, K. H.; Solomon, B. J.; Nagasaka, M.; Goto, K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer
    Meeting Abstract

    Drilon, A. E.; Kummar, S.; Lin, J. J.; Tan, D. S. W.; Moreno, V.; Leyvraz, S.; Dubashi, B.; Haresh, K. P.; Burcoveanu, D. I.; Neu, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Evaluation of the study of control arms in randomized clinical trials of cancer
    Meeting Abstract

    Jain, S. K.; Zauderer, M. G.; Sethi, T.; Schoen, M. W.; Rubinstein, S.; Nguyen, R. H. T.; Nagpal, S.; Mohan, S.; Madireddy, S.; Lythgoe, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study
    Meeting Abstract

    Brose, M. S.; Westphalen, C. B.; Kehl, K. L.; Pan, X.; Bernard-Gauthier, V.; Kurtinecz, M.; Guo, H.; Aris, V.; Brett, N. R.; Majdi, A. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save